左西孟旦治疗慢性充血性心力衰竭的效果被引量：4

EFFECT OF LEVOSIMENDAN ON CHRONIC CONGESTIVE HEART FAILURE

下载PDF

导出

摘要目的观察左西盂旦治疗慢性充血性心力衰竭（CHF）的临床效果。方法选取慢性CHF病人156例，随机分为实验组及对照组各78例。在常规治疗的基础上，实验组给予左西盂旦治疗，对照组给予多巴酚丁胺治疗。治疗2周后，观察比较两组NYHA心功能分级、左心室射血分数（LVEF）、每搏心输出量（sv）、血清N末端脑钠肽（NTpro—BNP）、尿素氮（BUN）、肌酐（cr）、电解质等的变化。结果与对照组比较，实验组治疗前后心功能分级、NTpro—BNP、LVEF、sV的变化差异有显著意义（Z=3．02，t=2．62～232．13，P〈O．05）。结论左西孟旦治疗慢性CHF，可显著改善心功能，提高LVEF和SV，降低NTpro—BNP水平。 Objective To evaluate clinical efficacy of levosimendan in the treatment of patients with chronic congestive heart failure （CCHF）. Methods A total of 156 CCHF patients were evenly randomized to experimental group and control group. In addition to conventional therapy, patients in the experimental group were given levosimendan, and those in the control group received dobutamine. Two weeks after the therapy, the following items were observed and compared between the two groups.. NY- HA classification, LVEF, SV, NTpro-BNP, blood glucose, BUN, Cr and electrolyte. Results Compared with the control group, the differences of NYHA functional classification, NTpro BNP, LVEF and SV between before and after treatment in the experimental group were significant （Z=3.02,t=2.62-232.13,P〈0.05）. Conclusion Levosimendan can improve heart function, increase LVEF and SV, and lower NTpro BNP in patients with chronic congestive heart failure.

作者姜少燕邹平曲蕊曹广智安毅

机构地区青岛大学医学院附属心血管病医院心内科青岛大学医学院附属心血管病医院药剂科青岛大学医学院附属医院心内科

出处《青岛大学医学院学报》 CAS 2014年第1期16-18,共3页 Acta Academiae Medicinae Qingdao Universitatis

关键词左西孟旦多巴酚丁胺心力衰竭充血性治疗结果 levosimendan dobutamine heart failure, congestive treatment outcome

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1LANDMESSER U, DREXLER H. Update on inotropic therapy in the management of acute heart failure [J]. Curr Treat Options Cardiovasc Med, 2007,9: 443-449.
2SONNTAG S, SUNDBERG S, LEHTONEN L A, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous translumial coronary angioplasty in acute myocardial ischemia[J]. J Am Call Cardi- 01. 2010.43(12): 2177-2182.
3王云飞,刘仁光,姜凤伟.左西孟旦治疗重度失代偿性心力衰竭的临床观察[J].中国药房,2011,22(30):2856-2858. 被引量：17
4陈晓飞.左西孟旦——心力衰竭治疗新药[J].中国药房,2011,22(10):881-881. 被引量：14
5GROSSINI E, MOLINARI C, CAIMMI P P, et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K (ATP) channel[J]. BrJ Pharmacal. 2009,156(2):250.
6FARMAKIS D, PARISSIS J T, BISTOLA V, et al. Plasma B-type natriuretic peptide reduction predicts longterm response to levosimendan therapy in acutely decompensated chronic heart failure[J]. Int J Cardiol. 2010,139(1): 75-79.

二级参考文献9

1Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study) :a randomised double-blind trial[J]. Lancet, 2002,360 (9 328) : 196.
2Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure [J]. Eur J Heart Fail, 2004,6 (4) : 501.
3Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study [J]. Circulation, 2002,106 (24) :3 068.
4Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of thd European Society of Cardiology[J]. Eur Heart J, 2005,26(4) :384.
5Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy [J]. JAm Coil Cardiol, 2005, 46(1):65.
6Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial [J]. J Cardiovasc Pharmacol, 1999, 34 (2) : 219.
7Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure[J]. JAm Coll Cardiol,2000 ,36( 6 ) : 1 903.
8Moiseyev VS, Poder P , Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized , placebo-controlled, double-blind study ( RUSSLAN ) [J]. Eur Heart J, 2002, 23(18) : 1 422.
9傅毅.钙增敏剂类心衰治疗药左西孟坦(levosimendan)[J].国外医药（合成药．生化药．制剂分册）,2001,22(5):316-316. 被引量：15